profit from every $100 of sales.
$0$100
Xencor
$37.09-2.73% today
+165.1% in 1 year
1-year low $10.411-year high $39.97
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Xencor sold, what it kept, and what it did with the cash.
Sales went from $165 million in 2022 to $126 million in 2025, with -$91.9 million of profit last year.
SalesProfit
Xencor vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Xencor | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Xencor's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 165 | 175 | 110 | 126 | |
| – | – | – | – | |
| -82 | -132 | -178 | -178 | |
| -46 | -102 | -186 | -47 | |
| -55 | -133 | -233 | -92 | |
| -0.93 | -2.08 | -3.58 | -1.24 | |
| – | – | – | – | |
| -50.1% | -75.8% | -161.5% | -141.4% | |
| -33.5% | -76.2% | -210.5% | -73.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 846 | 965 | 952 | 875 |
| Cash | 54 | 54 | 41 | 54 |
| Total debt | 60 | 252 | 232 | 188 |
| Total liabilities | 119 | 303 | 278 | 240 |
| 727 | 662 | 678 | 636 | |
| 60 | 61 | 65 | 74 | |
| -5.5% | -9.8% | -17.2% | -5.5% | |
| -7.6% | -20.1% | -34.3% | -14.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 24 | -78 | -202 | -135 | |
| 43 | 21 | 10 | 3 | |
| -19 | -99 | -212 | -138 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 49 | 54 | 53 | 43 |
Valuation
- –
- –
- –
- 1.8×
- 22.2×
- –
- –
- -5.0%
- -3.3%
- 0.0%
Profitability
- 92.0%
- -141.4%
- -73.2%
- -87.9%
- -30.6%
- -10.1%
- -28.8%
- -23.4%
- -32.0%
- 252.2%
Growth
- −8.6%
- –
- +33.6%
- –
- +6.2%
Financial health
- –
- 0.34
- 23.8%
- -7.6×
- 6.57
- 6.57
- 0.13
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 946
Bottom 2%of 872
Bottom 8%of 868
Bottom 20%of 986
What analysts expect
- Average price target
- $32.33
- Range
- $26.00 – $42.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -1.71 | -0.65 | −163.1% |
| Feb 25, 2026 | -0.09 | -0.64 | +85.9% |
| Nov 5, 2025 | -0.08 | -0.72 | +88.9% |
| Aug 6, 2025 | -0.41 | -0.78 | +47.4% |
| May 7, 2025 | -0.66 | -0.63 | −4.8% |
| Feb 27, 2025 | -0.62 | -0.81 | +23.5% |
| Nov 6, 2024 | -0.71 | -0.98 | +27.6% |
| Aug 5, 2024 | -1.07 | -0.85 | −25.9% |
News
Xencor reports promising kidney cancer drug results, plans late-stage trialSeeking Alpha · Oct 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
55No pass
Philip Fisher
42No pass
Peter Lynch
27No pass
Joel Greenblatt
2No pass
Charlie Munger
39No pass
Terry Smith
45No pass
Questions about Xencor
Is Xencor a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Xencor AI analysis
What does Xencor do?
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. It is in Biotechnology.
Does Xencor pay a dividend?
No. Xencor does not pay a dividend at the moment.
Is Xencor stock halal?
Yes. Xencor passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has Xencor stock done over the past year?
Up 165.1% over the past twelve months, to $37.09. It traded between $10.41 and $39.97 and is 7.2% below its high.
Who are Xencor's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Xencor's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.